Funding Opportunities

NIH Funding Opportunities

Notice of Clarification to Eligibility Criteria for PAR-16-268 "Limited Competition: Small Grant Program for NIAMS K08 and K23 Recipients (R03)"
Notice NOT-AR-17-019 from the NIH Guide for Grants and Contracts
Fri, 18 Aug 2017 09:19:22 EST

Notice to Update Research Objectives and to Announce Continued Funding for PAS-16-033 "Stimulating Hematology Investigation: New Endeavors (SHINE) (R01)"
Notice NOT-DK-17-016 from the NIH Guide for Grants and Contracts
Thu, 17 Aug 2017 01:54:27 EST

Notice of Change in Eligible Individuals for PAR-16-064 "Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21)"
Notice NOT-DK-17-017 from the NIH Guide for Grants and Contracts
Thu, 17 Aug 2017 02:24:34 EST

Notice of Intent to Publish a Funding Opportunity Announcement for NEI Audacious Goals Initiative: Translation-Enabling Models to Evaluate Survival and Integration of Regenerated Neurons in the Visual System (U24)
Notice NOT-EY-17-009 from the NIH Guide for Grants and Contracts
Tue, 15 Aug 2017 08:23:30 EST

Food Safety Preventive Controls and Produce Safety Standards: Building Competency in Latin America in Support of the U.S. Food Safety Modernization Act
Notice NOT-FD-17-012 from the NIH Guide for Grants and Contracts
Thu, 17 Aug 2017 10:19:57 EST

Clarification of RFA-HD-18-009 "Global Network for Women's and Children's Health Research (UG1)"
Notice NOT-HD-17-017 from the NIH Guide for Grants and Contracts
Fri, 18 Aug 2017 08:10:20 EST

Notice of Intent to Publish a Funding Opportunity Announcement for Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings (PATC3H) (UG3/UH3)
Notice NOT-HD-17-021 from the NIH Guide for Grants and Contracts
Tue, 15 Aug 2017 08:20:06 EST

Notice of NICHD's Participation in PAR-17-314 "Global Brain and Nervous System Disorders Research Across the Lifespan (R01)"
Notice NOT-HD-17-022 from the NIH Guide for Grants and Contracts
Tue, 15 Aug 2017 08:32:07 EST

Notice of NICHD's Participation in PAR-17-313 "Global Brain and Nervous System Disorders Research Across the Lifespan (R21) "
Notice NOT-HD-17-023 from the NIH Guide for Grants and Contracts
Tue, 15 Aug 2017 11:08:28 EST

Notice To Allow Additional Travel Funds for DAP Participants in: Initiative to Maximize Research Education in Genomics: Diversity Action Plan (R25)
Notice NOT-HG-17-013 from the NIH Guide for Grants and Contracts
Thu, 17 Aug 2017 11:13:44 EST

Notice of Website For Frequently Asked Questions (FAQs) About RFA-HG-17-006 Centers of Excellence in Ethical, Legal and Social Implications (ELSI) Research (CEER) (RM1)
Notice NOT-HG-17-015 from the NIH Guide for Grants and Contracts
Mon, 14 Aug 2017 10:39:25 EST

Notice of NHLBI Participation in PA-16-043 Revision Applications for Validation of Mobile/Wireless Health Tools for Measurement and Intervention (R01)"
Notice NOT-HL-17-534 from the NIH Guide for Grants and Contracts
Mon, 14 Aug 2017 10:35:35 EST

Notice of NHLBI's participation on PAR-17-450 "Limited Competition: Lasker Clinical Research Scholars Transition Award (R00)"
Notice NOT-HL-17-535 from the NIH Guide for Grants and Contracts
Thu, 17 Aug 2017 10:52:54 EST

Notice of NIMH's Interest in Pediatric Pharmacologic Trials in Autism Spectrum Disorders, directed at testing selective GABAergic agents
Notice NOT-MH-17-044 from the NIH Guide for Grants and Contracts
Thu, 17 Aug 2017 02:37:26 EST

Notice to Extend the Expiration Date for PAR-15-195 "NeuroNEXT Infrastructure Resource Access (X01)"
Notice NOT-NS-18-003 from the NIH Guide for Grants and Contracts
Mon, 14 Aug 2017 10:05:15 EST

Notice of Clarification of the Device Requirement for RFA-NS-17-005 "BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3)"
Notice NOT-NS-18-004 from the NIH Guide for Grants and Contracts
Fri, 18 Aug 2017 08:48:40 EST

Notice of Clarification of the Device Requirement for "BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (U44)"
Notice NOT-NS-18-006 from the NIH Guide for Grants and Contracts
Fri, 18 Aug 2017 09:11:34 EST

Request for Information (RFI): Infrastructure for Research in Nonhuman Primates
Notice NOT-OD-17-099 from the NIH Guide for Grants and Contracts
Mon, 14 Aug 2017 02:26:31 EST

Notice of Correction to NOT-OD-17-090 "Request for Information (RFI): Inviting Comments on the Environmental Influences on Child Health Outcomes (ECHO)-wide Cohort Data Collection Protocol"
Notice NOT-OD-17-103 from the NIH Guide for Grants and Contracts
Tue, 15 Aug 2017 11:12:34 EST

Notice of Correction to the Award Budget for the RFA-RM-17-017 "Model Organism Screening Center for the Undiagnosed Diseases Network (UDN) Phase II (U54)"
Notice NOT-RM-17-037 from the NIH Guide for Grants and Contracts
Thu, 17 Aug 2017 02:23:12 EST

Limited Competition: A Data Resource for Analyzing Blood and Marrow Transplants (U24)
Funding Opportunity RFA-CA-17-031 from the NIH Guide for Grants and Contracts. The purpose of this limited competition Funding Opportunity Announcement (FOA) is to solicit the Center for International Blood and Marrow Transplant Research (CIBMTR) a limited competition application for the continued support of the Data Resource for Analyzing Blood and Marrow Transplants program. The support for this FOA is to ensure the continued availability of the CIBMTR database as a resource to investigators, transplant physicians, and healthcare policy-makers.
Tue, 15 Aug 2017 02:48:08 EST

Chronic Kidney Disease in Children Central Biochemistry Laboratory (U24)
Funding Opportunity RFA-DK-17-034 from the NIH Guide for Grants and Contracts. The NIDDK invites Cooperative Agreement applications for an open competition for the Central Biochemistry Laboratory (CBL) of The Chronic Kidney Disease in Children (CKiD) consortium. The CBL will work cooperatively with the existing Clinical Coordinating Centers (CCCs) and Data Coordinating Center (DCC) of the study as a Consortium. Participant evaluations in some domains will be expanded, and follow-up will extend beyond the onset of End Stage Renal Disease (ESRD).
Thu, 17 Aug 2017 02:35:24 EST

Limited Competition for Continuation of the Prospective Study of Chronic Kidney Disease in Children Clinical Coordinating Centers (U01)
Funding Opportunity RFA-DK-17-502 from the NIH Guide for Grants and Contracts. The NIDDK, in collaboration with the NHLBI and NICHD, invites Cooperative Agreement applications for a limited competition from the two Clinical Coordinating Centers (CCCs) already involved in The Chronic Kidney Disease in Children (CKiD) consortium. The Clinical Centers will continue to evaluate enrolled participants, recruit new participants, and continue to work together cooperatively with the existing Data Coordinating Center (DCC) and Central Biochemistry Laboratory (CBL) of the study as a Consortium. Participant evaluations in some domains will be expanded, and follow-up will extend beyond the onset of End Stage Renal Disease (ESRD).
Thu, 17 Aug 2017 02:35:28 EST

Limited Competition for Continuation of the Prospective Study of Chronic Kidney Disease in Children Data Coordinating Center (U24)
Funding Opportunity RFA-DK-17-503 from the NIH Guide for Grants and Contracts. The NIDDK, in collaboration with the NHLBI and NICHD, invites Cooperative Agreement applications for a limited competition from the Data Coordinating Center (DCC) for The Chronic Kidney Disease in Children (CKiD) consortium. The DCC will work cooperatively with the existing Clinical Coordinating Centers (CCCs) and Central Biochemistry Laboratory (CBL) of the study as a Consortium. Participant evaluations in some domains will be expanded, and follow-up will extend beyond the onset of End Stage Renal Disease (ESRD).
Thu, 17 Aug 2017 02:35:31 EST

Limited Competition for the Continuation of the Chronic Renal Insufficiency Cohort (CRIC) Clinical Centers (U01)
Funding Opportunity RFA-DK-17-505 from the NIH Guide for Grants and Contracts. The purpose of this Limited Competition is to extend the Chronic Renal Insufficiency Cohort (CRIC) Study by continuing to support Clinical Centers that have previously enrolled and followed study participants. The CRIC Study is a multi-center, prospective, observational cohort study of men and women with chronic kidney disease (CKD). The operational components of the study include seven Clinical Centers and a Scientific and Data Coordinating Center (SDCC). The CRIC Study, established in 2001, has recruited approximately 5,500 study participants and followed them with annual in-person clinic visits and interim telephone contacts. The primary objective of this FOA is to continue the follow-up of enrolled participants with a focus on developing novel methods for clinical assessment of CKD and associated cardiovascular disease (CVD) risk factors. The expectation is that these novel assessment methods, combined with new analytic approaches, will identify endophenotypes of CKD, develop associations with CKD progression and acute kidney injury, and more fully characterize these diseases and their associated cardiovascular sequalae. It is anticipated that these studies will provide important insights into the courses and consequences of both CKD and CVD for health care providers and their patients with CKD to improve their management, including informing future clinical trials to reduce the burden of these chronic and varied diseases.
Fri, 18 Aug 2017 10:26:06 EST

Limited Competition for the Continuation of the Chronic Renal Insufficiency Cohort Scientific and Data Coordinating Center (U24)
Funding Opportunity RFA-DK-17-506 from the NIH Guide for Grants and Contracts. The purpose of this Limited Competition is to extend the Chronic Renal Insufficiency Cohort (CRIC) Study by continuing to support the Scientific and Data Coordinating Center. The CRIC Study is a multi-center, prospective, observational cohort study of men and women with chronic kidney disease (CKD). The operational components of the study include seven Clinical Centers and a Scientific and Data Coordinating Center (SDCC). The CRIC Study, established in 2001, has recruited approximately 5,500 study participants and followed them with annual in-person clinic visits and interim telephone contacts. The SDCC provides key leadership functions for this study in the areas of study organization, study design and implementation, overall management, and data management and analysis. The CRIC Clinical Centers will continue to follow-up previously enrolled participants under a separate FOA with a focus on developing novel methods for clinical assessment of CKD and associated cardiovascular diseases (CVD) risk factors. It is expected that these novel assessment methods, combined with new analytic approaches, will identify endophenotypes of CKD, develop associations with CKD progression and acute kidney injury, and more fully characterize these diseases and their associated cardiovascular sequalae. It is anticipated that these studies will provide important insights into the courses and consequences of CKD and CVD for both health care providers and their patients with CKD to improve their management, including informing future clinical trials to reduce the burden of these chronic and varied diseases. The SDCC will lead the study group to achieve the scientific goals of the next project period.
Fri, 18 Aug 2017 10:26:09 EST

Limited Competition for the Continuation of the Drug Induced Liver Injury Network (DILIN) Clinical Centers (U01)
Funding Opportunity RFA-DK-17-509 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is for a limited competition for clinical centers for the continuation of the Drug-induced Liver Injury Network (DILIN). The DILIN Clinical Centers are the components of the Network to identify, enroll and clinically characterize patients eligible for the DILIN. The companion RFA (RFA-DK-17-510) seeks to continue the Data Coordinating Center for DILIN Drug-induced liver injury (DILI) is one of the more challenging forms of liver disease; both in diagnosis and management. Several hundred drugs, nutritional supplements and herbal medications have been implicated in causing liver injury. Their clinical presentation can be highly variable and mimic almost any form of liver disease. Over the last 14 years, the DILIN Network throughout its publications (http://www.dilin.org/publications/) have become the major source of information and progress in understanding and possibly decreasing the burden of drug-induced liver injury for clinicians, hepatologists, researchers, and the public at large in the US and Worldwide.
Mon, 14 Aug 2017 12:03:56 EST

Limited Competition for the Continuation of the Drug Induced Liver Injury Network Data Coordinating Center (U24)
Funding Opportunity RFA-DK-17-510 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is for a limited competition for the continuation of the Data Coordinating Center of the Drug-induced Liver Injury Network (DILIN). The Data Coordinating Center will provide managerial, logistic, and analytic functions for the DILIN and built a collaboration with the National Center for Natural Products Research (NCNPR), University of Mississippi to attempt the identification of specific hepatotoxic ingredients in HDS implicated in liver toxicity. This RFA and companion RFA-DK-17-509 will seek the continuation of the Data Coordinating Center and six Clinical Centers
Mon, 14 Aug 2017 12:03:53 EST

Metabolomics Core for the Undiagnosed Diseases Network (UDN) Phase II (U01)
Funding Opportunity RFA-RM-17-015 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide the Metabolomics Core for Phase II of the Undiagnosed Diseases Network (UDN).
Tue, 15 Aug 2017 10:58:23 EST

Sequencing Core(s) for the Undiagnosed Diseases Network (UDN) Phase II (U01)
Funding Opportunity RFA-RM-17-016 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide support for sequencing for Phase II of the Undiagnosed Diseases Network (UDN).
Tue, 15 Aug 2017 10:58:21 EST

Model Organisms Screening Center for the Undiagnosed Diseases Network (UDN) Phase II (U54)
Funding Opportunity RFA-RM-17-017 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide a Model Organisms Screening Center for Phase II of the Undiagnosed Diseases Network (UDN). The Center will evaluate the pathogenicity and function of approximately 200 gene variants per year identified through the UDN. Responsive applications will propose to establish a screening strategy for selecting the most informative variants for analysis, and a research platform involving at a minimum Drosophila and zebrafish models. The screening pipeline may include additional small animal models or cell-based assays, as appropriate, to analyze the function of UDN gene variants in the context of the respective UDN participants disease phenotype. This initiative is funded through the NIH Common Fund which supports cross-cutting programs that are expected to have exceptionally high impact.
Tue, 15 Aug 2017 10:58:19 EST

Coordinating Center for the Undiagnosed Diseases Network (UDN) Phase II (U01)
Funding Opportunity RFA-RM-17-018 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide a Coordinating Center for Phase II of the Undiagnosed Diseases Network (UDN).
Tue, 15 Aug 2017 10:58:17 EST

Clinical Sites for the Undiagnosed Diseases Network (UDN) Phase II (U01)
Funding Opportunity RFA-RM-17-019 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide Clinical Sites for Phase II of the Undiagnosed Diseases Network (UDN).
Tue, 15 Aug 2017 10:58:15 EST

Biology of Lung, and Head and Neck Preneoplasias (R01)
Funding Opportunity PA-17-459 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks applications investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck (HN) cancers. Despite improved therapies and a deeper molecular understanding of lung and HN cancers, these tumors remain a major health problem in the United States and globally. While molecular markers of early injury to the aerodigestive epithelial field have been found, relatively little is known about the molecular mechanisms that initiate these preneoplasias and drive their progression to invasive cancer. A functional understanding of the key molecular changes involved in the formation and progression of lung and HN preneoplasias will enhance our knowledge of oncogenic progression and accelerate development of effective preventive and therapeutic strategies.
Tue, 15 Aug 2017 02:34:43 EST

Biology of Lung, and Head and Neck Preneoplasias (R21)
Funding Opportunity PA-17-460 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks applications investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck (HN) cancers. Despite improved therapies and a deeper molecular understanding of lung and HN cancers, these tumors remain a major health problem in the United States and globally. While molecular markers of early injury to the aerodigestive epithelial field have been found, relatively little is known about the molecular mechanisms that initiate these preneoplasias and drive their progression to invasive cancer. A functional understanding of the key molecular changes involved in the formation and progression of lung and HN preneoplasias will enhance our knowledge of oncogenic progression and accelerate development of effective preventive and therapeutic strategies.
Wed, 16 Aug 2017 02:54:53 EST

Symptom Cluster Characterization in Chronic Conditions (R21)
Funding Opportunity PA-17-461 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to encourage preclinical and clinical research and secondary data analysis on symptom cluster characterization that has potential to inform treatment and interventions that improve functional outcomes and quality of life in patients with chronic conditions.
Wed, 16 Aug 2017 09:35:32 EST

Symptom Cluster Characterization in Chronic Conditions (R01)
Funding Opportunity PA-17-462 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to encourage preclinical and clinical research and secondary data analysis on symptom cluster characterization that has potential to inform treatment and interventions that improve functional outcomes and quality of life in patients with chronic conditions.
Wed, 16 Aug 2017 09:35:28 EST

NINDS CREATE Bio Optimization Track for Biologics (U01)
Funding Opportunity PAR-17-456 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene and cell therapies) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic lead(s) that showed promise as a potential therapeutic agent as evidenced by convincing animal proof-of-concept studies. Therefore, at the end of this funding period, successful projects will have delivered and optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track. The CREATE Bio Development track is a later stage program focused on the development of optimized therapeutic candidates through Investigational New Drug (IND)-enabling studies and submission of an IND package to the Food and Drug Administration (FDA).
Mon, 14 Aug 2017 02:23:32 EST

NINDS CREATE Bio Optimization Track for Biologics (U44)
Funding Opportunity PAR-17-457 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports SBIRs in the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging modalities) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic agent(s) that showed promise as evidenced by relevant, rigorous, convincing in vivo studies. Therefore, at the end of this funding period, successful projects will have delivered an optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track.
Mon, 14 Aug 2017 02:21:54 EST

Population Assessment of Tobacco and Health (PATH) Biospecimen Access (X01)
Funding Opportunity PAR-17-458 from the NIH Guide for Grants and Contracts. The Population Assessment of Tobacco and Health (PATH) Study provides the scientific community with biospecimens (urine, plasma, and serum) and related research data on behaviors, attitudes, biomarkers and health outcomes associated with tobacco use in the U.S. This opportunity allows investigators to apply for access to the biospecimens from the PATH Study. Information about the PATH Study and this resource may be found on the PATH Study series page at the University of Michigans National Addiction and HIV Data Archive Program (NAHDAP) website, part of the Inter-University Consortium for Political and Social Researchs (ICPSR) website (https://doi.org/10.3886/Series606).
Tue, 15 Aug 2017 01:08:02 EST

Biology of Lung, and Head and Neck Preneoplasias (R21)
Funding Opportunity PAR-17-460 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks applications investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck (HN) cancers. Despite improved therapies and a deeper molecular understanding of lung and HN cancers, these tumors remain a major health problem in the United States and globally. While molecular markers of early injury to the aerodigestive epithelial field have been found, relatively little is known about the molecular mechanisms that initiate these preneoplasias and drive their progression to invasive cancer. A functional understanding of the key molecular changes involved in the formation and progression of lung and HN preneoplasias will enhance our knowledge of oncogenic progression and accelerate development of effective preventive and therapeutic strategies.
Tue, 15 Aug 2017 02:34:41 EST